Saturday, Feb 27, 2021

Panamá excluye de su tratamiento la hidroxicloroquina y azitromicina

Panama stops hydroxychloroquine treatment for COVID-19 patients

The Ministry of Health (Minsa) today decided to withdraw the use of hydroxychloroquine and azithromycin from the protocols for the Covid-19 patient treatment.

This was reported by the infectologist-pediatrician and member of the Advisory Committee for Covid-19 of the Minsa, Javier Nieto, after the scientific evidence produced by a study published by the medical journal The Lancet.

The research – the largest so far on the use of this medicine – took into account 96,000 patients in 671 hospitals in six continents, and were unable to confirm a benefit of hydroxychloroquine amongst the infected.

Nieto added the main medical contradiction of these drugs are associated with cardiac arrhythmias that could lead to death.

Meanwhile, the World Health Organization (WHO), after seeing the results of the study, decided to temporarily suspend the use of hydroxychloroquine in Covid-19 patients in its clinical trial called "Solidarity", in which Panama also participates.

Although a temporary pause of the hydroxychloroquine arm has been implemented within the global clinical trial, the other planned medications will continue to be tested.


Related Articles